Ziprasidone HCl 40 mg Oral Capsule
RxNorm 313776
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 313776 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: ziprasidone HCl 40 mg Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Ziprasidone 40 mg Oral Capsule
(Atom ID: 1464865)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely ziprasidone (as ziprasidone hydrochloride) 40 mg/1 each conventional release oral capsule (clinical drug)
(Atom ID: 12757532)
SYPrescribable
Synonym (SY):
Ziprasidone (as ziprasidone hydrochloride monohydrate) 40 mg Oral Capsule
(Atom ID: 4224538)
PTPrescribable
Designated preferred name (PT):
Ziprasidone (as ziprasidone hydrochloride) 40 mg oral capsule
(Atom ID: 12757904)
PSNPrescribable
Prescribable Name (PSN):
Ziprasidone HCl 40 mg Oral Capsule
(Atom ID: 6373205)
Patient Education
Ziprasidone
Ziprasidone is used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). It is also used to treat episodes of mania (frenzied, abnormally excited or irritated mood) or mixed episodes (symptoms of mania and depression that happen together) in patients with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Ziprasidone is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
[Learn More]
* Please review the disclaimer below.